**Name of Journal:** *World Journal of Gastrointestinal Pathophysiology*

**Manuscript NO:** 82233

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Polymorphism of genes encoding drug-metabolizing and inflammation-related enzymes for susceptibility to cholangiocarcinoma in Thailand**

You G *et al*. *CYP2E1*, *GSTT1* and risk for CCA

Gyokukou You, Lu Zeng, Hideaki Tanaka, Emi Ohta, Takahiro Fujii, Kazuhiko Ohshima, Masakazu Tanaka, Nobuyuki Hamajima, Chutiwan Viwatthanasittiphong, Mantana Muangphot, Dhiraphol Chenvidhya, Adisorn Jedpiyawongse, Banchob Sripa, Masanao Miwa, Satoshi Honjo

**Gyokukou You, Lu Zeng, Hideaki Tanaka, Emi Ohta, Takahiro Fujii, Kazuhiko Ohshima, Masanao Miwa,** Department of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama 526-0829, Shiga, Japan

**Masakazu Tanaka,** Division of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima 890-8544, Kagoshima, Japan

**Nobuyuki Hamajima,** Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Aichi, Japan

**Chutiwan Viwatthanasittiphong,** Department of Diagnostic and Interventional Radiology, Ubon Cancer Centre, Ubon Ratchathani 34000, Thailand

**Mantana Muangphot,** Department of Pathology, Ubon Cancer Centre, Ubon Ratchathani 34000, Thailand

**Dhiraphol Chenvidhya,** Department of Surgery, Ubon Cancer Centre, Ubon Ratchathani 34000, Thailand

**Adisorn Jedpiyawongse,** Research Division, National Cancer Institute, Bangkok 10400, Thailand

**Banchob Sripa,** Department of Pathology, Khon Kaen University, Khon Kaen 40002, Thailand

**Satoshi Honjo,** Department of Paediatirics, National Hospital Organization, Fukuoka National Hospital, Fukuoka 811-1394, Fukuoka, Japan

**Author contributions:** Miwa M secured funds and started the collaborative study in 1998 with the late Srivatanakul P who had been Thai side’s active organizer based on the National Cancer Institute, Bangkok, until her death in 2020; Viwatthanasittiphong C, Muangphot M, Chenvidhya D, Jedpiyawongse A, Sripa B, Honjo S, and Miwa M designed and conducted the epidemiological study; Sripa B measured anti-OV and providing microbiological advice; You G, Zeng L, Tanaka H, Ohta E, Fujii T, Ohshima K, Tanaka M, Hamajima N performed analyses concerning genetic polymorphisms; You G, Zeng L, Miwa M and Honjo S conducted statistical analyses and prepared the manuscript; All authors have read and approved the final manuscript.

**Supported by** Japan Society for the Promotion of Science, No. 21406011.

**Corresponding author: Satoshi Honjo, MD, MSc, PhD, Chief Doctor, Senior Researcher,** Department of Paediatirics, National Hospital Organization, Fukuoka National Hospital, 1-39-4 Yakatabaru, Minami-ku, Fukuoka 811-1394, Fukuoka, Japan. satoshihonjo@hotmail.com

**Received:** December 11, 2022

**Revised:** February 19, 2023

**Accepted:** March 15, 2023

**Published online:** March 22, 2023

**Abstract**

BACKGROUND

Cholangiocarcinoma (CCA) is an intractable cancer, and its incidence in northeastern Thailand is the highest worldwide. Infection with the liver fluke *Opisthorchis viverrini* (OV) has been associated with CCA risk. However, animal experiments have suggested that OV alone does not induce CCA, but its combination with a chemical carcinogen like nitrosamine can cause experimentally induced CCA in hamsters. Therefore, in humans, other environmental and genetic factors may also be involved.

AIM

To examine relations between risk for CCA and genetic polymorphisms in carcinogen-metabolizing and inflammation-related genes.

METHODS

This hospital-based case-control study enrolled 95 case-control pairs matched by age (± 5 years) and sex. We examined relations between risk for CCA and genetic polymorphisms in carcinogen-metabolizing and inflammation-related genes, serum anti-OV, alcohol consumption, and smoking. Polymorphisms of *CYP2E1*, *IL-6* (-174 and -634), *IL-10* (-819), and *NF-κB* (-94) and their co-occurrence with polymorphisms in the drug-metabolizing enzyme gene *GSTT1* or *GSTM1* were also analyzed.

RESULTS

Although CCA risk was not significantly associated with any single polymorphism, persons with the *GSTT1* wild-type and *CYP2E1* c1/c2 + c2/c2 genotype had an increased risk (OR = 3.33, 95%CI: 1.23-9.00) as compared with persons having the *GSTT1* wild-type and *CYP2E1* c1/c1 wild genotype. The presence of anti-OV in serum was associated with a 7- to 11-fold increased risk, and smoking level was related to an OR of 1.5-1.8 in multivariable analyses adjusted for each of the seven genetic polymorphisms.

CONCLUSION

In addition to infection with OV, gene-gene interactions may be considered as one of the risk factors for CCA development.

**Key Words:** *Opisthorchis*; Glutathione transferase; Cytochrome P-450 *CYP2E1*; Case-control study

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** You G, Zeng L, Tanaka H, Ohta E, Fujii T, Ohshima K, Tanaka M, Hamajima N, Viwatthanasittiphong C, Muangphot M, Chenvidhya D, Jedpiyawongse A, Sripa B, Miwa M, Honjo S. Polymorphism of genes encoding drug-metabolizing and inflammation-related enzymes for susceptibility to cholangiocarcinoma in Thailand. *World J Gastrointest Pathophysiol* 2023; 14(2): 21-33

**URL:** https://www.wjgnet.com/2150-5330/full/v14/i2/21.htm

**DOI:** https://dx.doi.org/10.4291/wjgp.v14.i2.21

**Core Tip:** Cholangiocarcinoma (CCA) is an intractable cancer, and its prevalence in northeastern Thailand is the highest worldwide. An inflammatory condition produced by infection with the liver fluke *Opisthorchis viverrini* (OV) has been associated with CCA risk, but the susceptibility of individuals has not been fully examined. Our study revealed that persons with the *GSTT1* wild-type and *CYP2E1* c1/c2 + c2/c2 genotype had an increased risk for developing CCA (OR = 3.33, 95%CI: 1.23-9.00). Therefore, both gene-gene interactions and OV infection should be considered as risk factors for cholangiocarcinogenesis.

**INTRODUCTION**

Cholangiocarcinoma (CCA) is a cancer of the hepatobiliary tract, and its incidence is extremely high in northeastern Thailand[1]. This is related to the lifestyle of the people of this area who often consume raw fish, which carries the risk of ingesting fish-borne parasites[2]. Infection with the liver fluke, *Opisthorchis viverrini* (OV), is a known CCA risk factor for inhabitants of northeastern Thailand[3-5], where approximately one-third of the population has been infected with OV[6,7]. Although infection with OV has been listed as a carcinogen to humans by The International Agency for Research on Cancer (IARC)[8], infection with OV alone is not sufficient for CCA development. Indeed, experiments with hamsters have suggested that parasitic infection alone is not sufficient to develop CCA. In fact, co-administration of a chemical carcinogen such as *N*-nitrosodimethylamine is necessary to induce CCA in hamsters[9]. In addition, genetic background related to the activation or detoxification of chemical carcinogens is reported to be involved in CCA risk[10]. Also, elevated plasma IL-6 was associated with increased risk of CCA in patients infected with OV[11]. Thus, maintenance of chronic infection, exposure to a chemical carcinogen(s), and genetic background may explain CCA risk in northeastern Thailand. We previously reported that infection with OV and genetic polymorphism of a drug-metabolizing enzyme gene, namely *GSTM1*, is related to CCA risk[5] and that the combined effect of polymorphisms of the genes *8-oxoguanine glycosylase 1* and *GSTM1* is also relevant CCA risk[12] in northeastern Thailand. Here, we report our analysis of the association between polymorphisms of inflammation-related genes *(IL-6, IL-10* and *NF-kB*), and *CYP2E1, GSTT1* and *GSTM1* with risk of developing CCA. We also analyzed potential interactions among genetic polymorphisms of these genes.

**MATERIALS AND METHODS**

This work was conducted after receiving the approval from the ethics committees of the Nagahama Institute of Bio-Science and Technology, Shiga, Japan, and the National Cancer Institute, Bangkok, Thailand.

***Study subjects***

All cases with CCA were identified between 1999 and 2005 upon a visit to the Ubon Ratchathani Cancer Centre in the northeastern province of Thailand, one of the cancer centers administered by the National Cancer Institute of Thailand. Diagnosis was based on abdominal ultrasonography by a single radiologist at Ubon Ratchathani Cancer Centre with serological supportive evidence including an elevated carbohydrate antigen 19-9 level (≥ 40 μ/mL). Each case was matched by sex and age (within 5 years) with each control subject who lived in the same Ubon Ratchathani area and visited Ubon Ratchathani Cancer Centre for health check-up. All control subjects were without any clinical, ultrasonographical, or serological abnormalities. Finally, the 95 case-control pairs having data for an antibody against infection with OV were employed although the number of subjects for each of the analyses involving genetic polymorphisms was not equal because the amount of blood samples was limited. Still, there was a narrow range (91-95) for the number of case-control pairs for each of the genetic polymorphisms examined (Table 1).

***OV infection***

Infection with OV was determined with an enzyme-linked immunosorbent assay using an antibody (“anti-OV”) raised against an OV antigen[13].

***DNA extraction***

Blood samples were frozen and stored at -80°C. DNA was extracted from 2 mL blood with the QIAGEN DNA Blood Midi kit[14].

***Analysis of GSTM1 and GSTT1 polymorphisms***

Polymorphisms in each of *GSTM1* and *GSTT1* were determined with polymerase chain reaction (PCR)[5] using the following primers: *GSTM1*, 5’-GAA CTC CCT GAA AAG CTA AAG C-3’ and 5’-GTT GGG CTC AAA TAT ACG GTG G-3’; *GSTT1*, 5’-TTC CTT ACT GGT CCT CAC ATC TC-3’ and 5’-TCA CCG GAT CAT GGC CAG CA-3’; *CYP1A1* (internal control), 5’-GAA CTG CCA CTT CAG CTG TCT-3’ and 5’-CAG CTG CAT TTG GAA GTG CTC-3’. Each 20-μl reaction contained 0.2 μM of each primer, 200 μM deoxyribonucleoside triphosphates (dNTPs), 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.5), 1.5 mmol/L MgCl2, approximately 6 ng DNA, and *Taq* DNA polymerase (AmpliTaqGold; Cetus PerkinElmer, Norwalk, CT). The PCR cycling parameters were 3 min at 95°C (initial denaturation) followed by 45 cycles of 1 min at 95°C, 30 sec at 59°C, and 1 min at 72°C, with a final 10-min extension step. The PCR products (299 bp for *GSTM1*, 507 bp for *GSTT1*) were separated on a 2% agarose gel.

***Analysis of CYP2E1 polymorphisms***

The 5’-flanking *Rsa*I site polymorphism of *CYP2E1* was detected by PCR combined with restriction-fragment-length polymorphism analysis (PCR-RFLP). The forward and reverse primers were 5’-CCA GTC GAG TCT ACA TTG TCA-3’ and 5’-TTC ATT CTG TCT TCT AAC TGG-3’, respectively. Each 20-μl reaction contained 0.2 μM of each primer, 200 μM dNTPs, 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.5), 1.5 mmol/L MgCl2, approximately 6 ng DNA, and *Taq* DNA polymerase. The PCR cycling parameters were 12 min at 95°C (initial denaturation) followed by 40 cycles of 1 min at 95°C, 30 sec at 60°C, and 1 min at 72°C, with a final 10-min extension step at 72°C. A 10-µl aliquot of the PCR products was digested with 0.2 U of the restriction enzyme *Rsa*I (GTaU) (TOYOBO Co., Ltd., Japan) for 16 h at 37°C. The resulting fragments were separated by 3% agarose gel electrophoresis and stained with ethidium bromide. The expected PCR product was 410 bp. Upon digestion with *Rsa*I, the c1/c1 wild-type homozygotes had fragments of 360 and 50 bp, the c1/c2 heterozygotes had fragments of 410, 360 and 50 bp, and the c2/c2 variant homozygotes had a fragment of 410 bp[15].

***Analysis of IL-6 (rs1800795) polymorphisms***

Polymorphism -174 (G/C) (rs1800795) of *IL-6* was detected by PCR-RFLP with forward primer 5’-ATG CCA AGT GCT GAG TCA CTA-3’ and reverse primer 5’-TCG AGG GCA GAA TGA GCC TC-3’. Each 20-μl reaction contained 0.2 μM of each primer, 200 μM dNTPs, 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, approximately 6 ng DNA, and *Taq* DNA polymerase. The PCR cycling parameters were 10 min at 95°C (initial denaturation) followed by 40 cycles of 30 sec at 95°C, 30 sec at 54°C, and 40 sec at 72°C, with a final 10-min extension step at 72°C. A 10-µl aliquot of the PCR products was digested with 0.2 U of the restriction enzyme *Nla*III (CATG↓) (New England Biolabs, Japan) at 37°C for 16 h and separated by PAGE (10% polyacrylamide gel). The expected PCR product was 308 bp. Upon digestion with *Nla*III, the G/G wild-type homozygotes had fragments of 233 and 75 bp, the G/C heterozygotes had fragments of 233, 121, 112 and 75 bp, and the C/C variant homozygotes had fragments of 121, 112 and 75 bp[16].

***Analysis of IL-6 (rs1800796) polymorphisms***

Polymorphism -634 G/C (rs1800796) of *IL-6* was analyzed by PCR with confronting two-pair primers[17]. The four primers used were *IL-6*-634 F1 5’-CCT CTA AGT TGG GCT GAA GCA GG-3' and *IL-6*-634 R1 5’-GTT CTG GCT CTC CCT GTG AGG-3’ for amplifying the variant type, and *IL-6*-634 F2 5’-CCA GGC AGT TCT ACA ACA GCC G-3’ and *IL-6*-634 R2 5’-TGA GTT TCC TCT GAC TCC ATC GC-3’ for amplifying wild type. Each 25-μl reaction contained 0.2 μM of each primer, 200 μM dNTPs, 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 2 mmol/L MgCl2, approximately 6 ng DNA, and *Taq* DNA polymerase. The PCR cycling parameters were 10 min at 95°C (initial denaturation) followed by 36 cycles of 1 min at 95°C, 1 min at 65°C, and 1 min at 72°C, with a final 5-min extension step at 72°C. The PCR products were separated by PAGE. The G/G wild-type homozygotes had fragments of 157 and 240 bp, G/C heterozygotes had fragments of 125, 157, 240 and 75 bp, and the C/C variant homozygotes had fragments of 125 and 240 bp.

***Analysis of IL-10 (rs1800871) polymorphisms***

Polymorphism -819 T/C (rs1800871) of *IL-10* was analyzed by PCR-RFLP. The forward and reverse primers were *IL-10*-819 F 5’-TCA TTC TAT GTG CTG GAG ATG G-3’ and *IL-10*-819 R 5’-TGG GGG AAG TGG GTA AGA GT-3’, respectively. Each 20-μl reaction contained 0.2 μM of each primer, 200 μM dNTPs, 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 2 mmol/L MgCl2, approximately 6 ng DNA, and *Taq* DNA polymerase. The PCR cycling parameters were 5 min at 95°C (initial denaturation) followed by 40 cycles of 30 sec at 95°C, 45 sec at 59°C, and 1 min at 72°C, with a final 10-min extension step at 72°C. A 10-µl aliquot of the PCR products was digested with 0.03 U of the restriction enzyme *Mae*III (↓GTNAC) (Roche Diagnostics GmbH Germany) for 16 h at 55°C and separated by PAGE. The expected PCR product was 209 bp. Following digestion with *Mae*III, the T/T wild-type homozygotes had a fragment of 209 bp, the T/C heterozygotes had fragments of 209, 125 and 84 bp, and the C/C variant homozygotes had fragments of 209 and 84 bp[18].

***Analysis of NF-κB polymorphisms***

Polymorphism -94 ins/del ATTG of the *NF-κB* promoter was determined by PCR-RFLP. The forward and reverse primers were 5’-TTT AAT CTG TGA AGA GAT GTG AAT-3’ and 5’-CTA GCA GGG CGC TCC CGA AT-3’, respectively. Each 20-μl reaction contained 0.2 μM of each primer, 200 μM dNTPs, 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, approximately 6 ng DNA, and *Taq* DNA polymerase. The PCR cycling parameters were 10 min at 95°C (initial denaturation) followed by 40 cycles of 30 sec at 95°C, 1 min at 56°C, and 1 min at 72°C, with a final 10-min extension at 72°C. A 10-µl aliquot of the PCR products was digested with 2 U of the restriction enzyme *PflMI* (New England Biolabs Inc., Japan) at 37°C for 16 h and separated by PAGE. The expected PCR product was 254 bp. Upon digestion with *PflMI*, the del/del ATTG wild-type homozygotes had a fragment of 254 bp, the ins/del heterozygotes had fragments of 254 and 206 bp, and the ins/ins variant homozygotes had a fragment of 206 bp[19].

***Data collection for lifestyle-related factors***

Smoking and alcohol consumption status were ascertained alongside dietary habits at the hospital by local health personnel using a structured questionnaire used in previous studies[5,12]. Smoking status was classified into four categories: Never, occasional, former, and current. A current smoker was defined as smoking at least 1 cigarette *per* day, whereas the former smoker was defined as having stopped smoking regularly at least 1 year prior to our study. Alcohol consumption status was classified the same as for smoking status into four categories: Never, occasional, former, and current. “Current” drinker was defined as drinking more than once a week, whereas “former” drinker was defined as having stopped regular drinking at least 1 year prior to the study.

***Statistical analysis***

CCA risk attributable to infection with OV was defined as positivity for anti-OV, and the potential contributions of genetic polymorphisms of genes encoding inflammation-related enzymes were examined by calculating an OR. Each OR was calculated using a conditional logistic regression model, keeping matched case-control pairs. Interactions between each of the genetic polymorphisms of the inflammation-related genes and each of the metabolic enzyme genes were first examined using a log-likelihood ratio test. The tests compared the main effect with no interaction terms with a full model that included the interaction term for the variables concerned. When the p value for the log-likelihood ratio statistic was < 0.1, we calculated the OR owing to the co-occurrence of two genetic polymorphisms. Three subjects lacked data for alcohol consumption, and two lacked data for smoking status (Table 1). Most of the multivariable statistical analyses were performed with imputation for the missing data for these five subjects and produced comparable results (Tables 2-4). All statistical analyses were performed with the statistical package STATA 16.1 (College Station, TX, USA), and statistical significance was defined as *P* < 0.05 unless indicated otherwise.

Although the CCA-related risk of infection with OV among the current study subjects was reported in the multivariable analyses that included the interaction terms between the *GSTM1* and *hOGG1* polymorphisms in our previous study[12], a crude or adjusted OR for each polymorphism has not been reported. Data for CCA risk owing to polymorphism of *GSTM1* or *GSTT1* alone also has not been reported[12]. Findings for those factors are, thus, reported in the present study.

**RESULTS**

Concerning environmental factors, we confirmed the strong association between anti-OV-positive individuals and CCA risk adjusted for smoking status and alcohol consumption (Table 2). The OR values (95%CI) for a one-category change in smoking category (never, occasional, former, current) were approximately 1.5 regardless of the particular genetic polymorphism(s) examined or whether imputed data were included (Table 3). Alcohol consumption was not materially related to CCA risk (Table 3).

There was no significant association between polymorphisms for any of the inflammation-related genes or drug-metabolizing genes and CCA risk. When an inflammation-related gene (*IL-6*, *IL-10*, *NF-kB*) wild-type genotype was used as the reference, CCA risk was not significantly associated with any homozygous or heterozygous genotype (Table 4). Likewise, when the *GSTT1* wild-type genotype was used as the reference, CCA risk was not significantly associated with the null genotype. Similarly, when the *GSTM1* wild-type genotype was used as the reference, CCA risk was not significantly associated with the null genotype. When the *CYP2E1* c1/c1 wild-type genotype was used as the reference, CCA risk was not significantly associated with c1/c2, c2/c2, or the combination of the c1/c2 + c2/c2 genotypes (Table 4).

***Gene-gene interactions between GSTT1 and CYP2E1***

Interaction of the *CYP2E1* polymorphism and the *GSTT1* polymorphisms was suggested by a p value of 0.003, whereas other interactions between drug-metabolizing enzyme genes (*GSTM1* or *GSTT1*) and other genetic polymorphisms were not substantiated (*P* > 0.10). Persons with the *GSTT1* wild-type plus *CYP2E1* c1/c2 + c2/c2 genotype had an increased risk for CCA (OR = 3.33, 95%CI: 1.23-9.00) as compared with persons having the *GSTT1* wild-type plus *CYP2E1* c1/c1 wild-type genotype that was used as the reference (Table 5).

**DISCUSSION**

Early diagnosis of CCA is difficult, and most patients die within a year after diagnosis[20]. Identification of risk factors and means of preventing cholangiocarcinogenesis is thus highly desirable. We confirmed that positivity for anti-OV constitutes a significant risk factor for CCA, as reported previously[3,5,21]. Smoking was not a significant risk factor for CCA, whereas alcohol consumption was in fact related to increased risk as we reported previously for subjects (and matched controls) recruited from another part of northern Thailand[5] In the present study, control subjects were persons seeking a health check-up and thus possibly may have led a relatively healthier lifestyle compared with our experimental subjects. However, the discordance between the findings on smoking and alcohol drinking of the two studies are not yet explained. Although we did not find any significant association between CCA risk and polymorphisms in inflammation-related genes (*IL-6*, *IL-10*, *NF-kB*) or in drug metabolism-related genes (*CYP2E1, GSTT1* and *GSTM1*), persons with the *GSTT1* wild-type plus *CYP2E1* c1/c2 + c2/c2 genotype had a 3-fold greater risk than persons having the *GSTT1* wild-type plus *CYP2E1* c1/c1 wild-type genotype that was used as the reference. Hayashi *et al*[22] reported that the c2/c2 homozygous sequence placed upstream of the SV40 promoter and *chloramphenicol acetyltransferase* gene enhanced the expression of that gene, and the enhancement of expression by the c2/c2 sequence was about 10-fold that by the c1/c1 sequence. Thus, it is possible that CYP2E1 is expressed at a higher level in the presence of the c2/c2 sequence than in the presence of the c1/c1 sequence, which is consistent with the known function of CYP2E1 as a carcinogen-activating enzyme[23,24]. Because the numbers of cases and controls were not large, the conclusions from this work should be confirmed in a future study with more cases and controls. In addition, genes encoding other drug-metabolizing enzymes should also be tested with respect to gene-gene interactions.

**CONCLUSION**

The presence of anti-OV in serum was associated with a 7- to 11-fold increased risk for CCA independently of the genetic polymorphisms of carcinogen-metabolizing and inflammation-related genes. While any single polymorphism was not significantly associated with CCA risk, persons with the *GSTT1* wild-type and *CYP2E1* c1/c2 + c2/c2 genotype had a 3-fold increased risk as compared with persons having the *GSTT1* wild-type and *CYP2E1* c1/c1 wild genotype. In addition to infection with OV, gene-gene interactions may be considered as one of the risk factors for CCA development.

**ARTICLE HIGHLIGHTS**

***Research background***

Cholangiocarcinoma (CCA) is a cancer of the hepatobiliary tract, and its incidence is extremely high in northeastern Thailand. This is related to the lifestyle of the inhabitants of this area consuming often raw fish, which carries the risk of ingesting fish-borne parasites, *Opisthorchis viverrini* (OV), a known CCA risk factor. While infection with OV has been listed as a carcinogen to humans by The International Agency for Research on Cancer, the parasitic infection alone is not sufficient to develop CCA; in fact, co-administration of a chemical carcinogen such as *N*-nitrosodimethylamine is necessary to induce CCA in animal model. In addition, genetic background related to the activation or detoxification of chemical carcinogens is reported to be involved in CCA risk. Also, elevated plasma IL-6 was associated with increased risk of CCA in patients infected with OV.

***Research motivation***

We already reported that infection with OV and genetic polymorphism of a drug-metabolizing enzyme gene, namely *GSTM1*, is related to CCA risk and that the combined effect of polymorphisms of the genes *8-oxoguanine glycosylase 1* and *GSTM1* is also relevant CCA risk in northeastern Thailand. In the present study, we further investigated possible associations of maintenance of chronic infection, exposure to a chemical carcinogen(s) and genetic background with CCA risk in northeastern Thailand.

***Research objectives***

To examine relations between risk for CCA and genetic polymorphisms in carcinogen-metabolizing (*CYP2E1*, *GSTT1* and *GSTM1*) and inflammation-related genes (*IL-6, IL-10* and *NF-kB*), and potential interactions among genetic polymorphisms of these genes on the CCA risk.

***Research methods***

All cases with CCA were identified between 1999 and 2005 upon a visit to the Ubon Ratchathani Cancer Centre in the northeastern province of Thailand. This hospital-based case-control study enrolled 95 case-control pairs matched by age (± 5 years) and sex. We examined relations between risk for CCA and genetic polymorphisms in carcinogen-metabolizing and inflammation-related genes, serum anti-OV, alcohol consumption, and smoking. Smoking and alcohol consumption status were ascertained using a structured questionnaire used in previous studies. Conditional logistic regression was employed to estimate CCA risk as OR due to each of genetic polymorphisms and possible interactions of those polymorphisms.

***Research results***

Although any single polymorphism was not significantly associated with CCA risk, persons with the *GSTT1* wild-type and *CYP2E1* c1/c2 + c2/c2 genotype had a 3-fold increased risk as compared with persons having the *GSTT1* wild-type and *CYP2E1* c1/c1 wild genotype. The presence of anti-OV in serum was associated with a 7- to 11-fold increased risk for CCA independently of the genetic polymorphisms of carcinogen-metabolizing and inflammation-related genes.

***Research conclusions***

An inflammatory condition produced by infection with OV indicated as raised anti-OV in serum has been associated with CCA risk. Our study added the finding that persons with the *GSTT1* wild-type and *CYP2E1* c1/c2 + c2/c2 genotype had a 3-fold increased risk for developing CCA. Therefore, both gene-gene interactions and OV infection should be considered as risk factors for cholangiocarcinogenesis in northeastern Thailand.

***Research perspectives***

CCA is still an intractable cancer. While our study revealed the interaction of polymorphisms of *GSTT1* and *CYP2E1* possibly contributes to development of CCA, the numbers of cases and controls were not large. The conclusions from this work should be confirmed in a future study with more cases and controls. In addition, genes encoding other drug-metabolizing enzymes should also be tested with respect to gene-gene interactions.

**ACKNOWLEDGEMENTS**

We thank both the case and control subjects for their participation in our study and all the community hospitals for their generous assistance in interviewing and collecting the specimens from all the subjects. The late Dr. Srivatanakul had started the collaborative study with Professor Miwa in 1998 concerning an etiological investigation on CCA in Thailand and continued to be the Thai side’s active organizer based on the National Cancer Institute, Bangkok, until her death in 2020. As such, she actively participated in the planning, epidemiological investigation (including patient and control subject recruitment) and giving helpful comments on data analyses.

**REFERENCES**

1 **Kamsa-Ard S**, Luvira V, Suwanrungruang K, Kamsa-Ard S, Luvira V, Santong C, Srisuk T, Pugkhem A, Bhudhisawasdi V, Pairojkul C. Cholangiocarcinoma Trends, Incidence, and Relative Survival in Khon Kaen, Thailand From 1989 Through 2013: A Population-Based Cancer Registry Study. *J Epidemiol* 2019; **29**: 197-204 [PMID: 30078813 DOI: 10.2188/jea.JE20180007]

2 **Sripa B**, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM, Loukas A. The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. *Trends Parasitol* 2012; **28**: 395-407 [PMID: 22947297 DOI: 10.1016/j.pt.2012.07.006]

3 **Parkin DM**, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, L'Abbé KA, Wild CP. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. *Int J Cancer* 1991; **48**: 323-328 [PMID: 1645697 DOI: 10.1002/ijc.2910480302]

4 **Srivatanakul P**, Ohshima H, Khlat M, Parkin M, Sukarayodhin S, Brouet I, Bartsch H. Endogenous nitrosamines and liver fluke as risk factors for cholangiocarcinoma in Thailand. *IARC Sci Publ* 1991; 88-95 [PMID: 1649794]

5 **Honjo S**, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, Todoroki T, Jedpiyawongse A, Kittiwatanachot P, Sripa B, Deerasamee S, Miwa M. Genetic and environmental determinants of risk for cholangiocarcinoma *via* Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. *Int J Cancer* 2005; **117**: 854-860 [PMID: 15957169 DOI: 10.1002/ijc.21146]

6 **Kaewpitoon N**, Kaewpitoon SJ, Pengsaa P. Opisthorchiasis in Thailand: review and current status. *World J Gastroenterol* 2008; **14**: 2297-2302 [PMID: 18416453 DOI: 10.3748/wjg.14.2297]

7 **Prakobwong S**, Suwannatrai A, Sancomerang A, Chaipibool S, Siriwechtumrong N. A Large Scale Study of the Epidemiology and Risk Factors for the Carcinogenic Liver Fluke Opisthorchis viverrini in Udon Thani Province, Thailand. *Asian Pac J Cancer Prev* 2017; **18**: 2853-2860 [PMID: 29072436 DOI: 10.22034/APJCP.2017.18.10.2853]

8 Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 121-175 [PMID: 7715069]

9 **Thamavit W**, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. *Cancer Res* 1978; **38**: 4634-4639 [PMID: 214229]

10 **Miwa M**, Honjo S, You G, Tanaka M, Uchida K, Srivatanakul P, Khuhaprema T, Loilome W, Techasen A, Wongkham C, Limpaiboon T, Yongvanit P, Wongkham S. Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand. *World J Gastrointest Pathophysiol* 2014; **5**: 570-578 [PMID: 25401000 DOI: 10.4291/wjgp.v5.i4.570]

11 **Sripa B**, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, Sithithaworn P, Periago MV, Bhudhisawasdi V, Yonglitthipagon P, Mulvenna J, Brindley PJ, Loukas A, Bethony JM. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. *PLoS Negl Trop Dis* 2012; **6**: e1654 [PMID: 22629477 DOI: 10.1371/journal.pntd.0001654]

12 **Zeng L**, You G, Tanaka H, Srivatanakul P, Ohta E, Viwatthanasittiphong C, Matharit M, Chenvidhya D, Jedpiyawongse A, Tanaka M, Fujii T, Sripa B, Ohshima K, Miwa M, Honjo S. Combined effects of polymorphisms of DNA-repair protein genes and metabolic enzyme genes on the risk of cholangiocarcinoma. *Jpn J Clin Oncol* 2013; **43**: 1190-1194 [PMID: 24049014 DOI: 10.1093/jjco/hyt138]

13 **Sripa B**, Kaewkes S. Relationship between parasite-specific antibody responses and intensity of Opisthorchis viverrini infection in hamsters. *Parasite Immunol* 2000; **22**: 139-145 [PMID: 10672195 DOI: 10.1046/j.1365-3024.2000.00286.x]

14 QIAamp DNA Blood Midi/Maxi Handbook. 2nd ed: QIAGEN; 2007. Available from: file:///C:/Users/m\_miwa/Downloads/HB-0339-003-1090244-HB-QIAamp-DNA-Blood-MidiMaxi-0215-WW.pdf

15 **Guo YM**, Wang Q, Liu YZ, Chen HM, Qi Z, Guo QH. Genetic polymorphisms in cytochrome P4502E1, alcohol and aldehyde dehydrogenases and the risk of esophageal squamous cell carcinoma in Gansu Chinese males. *World J Gastroenterol* 2008; **14**: 1444-1449 [PMID: 18322963 DOI: 10.3748/wjg.14.1444]

16 **Lagmay JP**, London WB, Gross TG, Termuhlen A, Sullivan N, Axel A, Mundy B, Ranalli M, Canner J, McGrady P, Hall B. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). *Clin Cancer Res* 2009; **15**: 5234-5239 [PMID: 19671870 DOI: 10.1158/1078-0432.CCR-08-2953]

17 **Hamajima N**. PCR-CTPP: a new genotyping technique in the era of genetic epidemiology. *Expert Rev Mol Diagn* 2001; **1**: 119-123 [PMID: 11901796 DOI: 10.1586/14737159.1.1.119]

18 **Edwards-Smith CJ**, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. *Hepatology* 1999; **30**: 526-530 [PMID: 10421663 DOI: 10.1002/hep.510300207]

19 **Yalcin B**, Atakan N, Alli N. The functional role of nuclear factor kappa-kappaB1 -94 ins/del ATTG promotor gene polymorphism in Behçet's disease: an exploratory study. *Clin Exp Dermatol* 2008; **33**: 629-633 [PMID: 18616724 DOI: 10.1111/j.1365-2230.2008.02786.x]

20 **Chaiteerakij R**, Pan-Ngum W, Poovorawan K, Soonthornworasiri N, Treeprasertsuk S, Phaosawasdi K. Characteristics and outcomes of cholangiocarcinoma by region in Thailand: A nationwide study. *World J Gastroenterol* 2017; **23**: 7160-7167 [PMID: 29093624 DOI: 10.3748/wjg.v23.i39.7160]

21 **Srivatanakul P**, Parkin DM, Jiang YZ, Khlat M, Kao-Ian UT, Sontipong S, Wild C. The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. A correlation study. *Cancer* 1991; **68**: 2411-2417 [PMID: 1657355 DOI: 10.1002/1097-0142(19911201)68:11<2411::aid-cncr2820681114>3.0.co;2-0]

22 **Hayashi S**, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. *J Biochem* 1991; **110**: 559-565 [PMID: 1778977 DOI: 10.1093/oxfordjournals.jbchem.a123619]

23 **Tsutsumi M**, Matsuda Y, Takada A. Role of ethanol-inducible cytochrome P-450 2E1 in the development of hepatocellular carcinoma by the chemical carcinogen, N-nitrosodimethylamine. *Hepatology* 1993; **18**: 1483-1489 [PMID: 8244274]

24 **Chowdhury G**, Calcutt MW, Nagy LD, Guengerich FP. Oxidation of methyl and ethyl nitrosamines by cytochrome P450 2E1 and 2B1. *Biochemistry* 2012; **51**: 9995-10007 [PMID: 23186213 DOI: 10.1021/bi301092c]

**Footnotes**

**Institutional review board statement:** This work was conducted after receiving the approval from the ethics committees of the Nagahama Institute of Bio-Science and Technology, Shiga, Japan, and the National Cancer Institute, Bangkok, Thailand.

**Informed consent statement:** Informed written consent was obtained from the case and control subjects for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All authors declare that they have no competing interests.

**Data sharing statement:** Consent for data sharing was not obtained.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Japanese Cancer Association, 23519.

**Peer-review started:** December 11, 2022

**First decision:** February 8, 2023

**Article in press:** March 15, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lim SYM, Malaysia; Mohamad Hanif EA, Malaysia **S-Editor:** Liu GL **L-Editor:** A **P-Editor:** Liu GL

**Table 1 Number of subjects with non-missing and with missing values for serum anti-*Opisthorchis viverrini*, alcohol consumption, and smoking dependent on each matched-pair analysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Principle independent variable** | **Number of matched pairs** | **Anti-OV** | **Alcohol consumption** | **Smoking** |
| **Missing** | **Non-missing** | **Missing** | **Non-missing** | **Missing** | **Non-missing** |
| Anti-OV | 95 | Not applicable | 3 | 187 | 2 | 188 |
| *GSTM1* | 95 | 10 | 180 | 2 | 188 | 2 | 188 |
| *GSTT1* | 95 | 10 | 180 | 2 | 188 | 2 | 188 |
| *CYP2E1* | 93 | 9 | 177 | 2 | 184 | 2 | 184 |
| *IL6*, -634 G/C | 91 | 10 | 172 | 2 | 180 | 2 | 180 |
| *IL6*, -175 G/C | 92 | 10 | 174 | 2 | 182 | 2 | 182 |
| *IL10*, -819 T/C  | 91 | 10 | 172 | 2 | 180 | 2 | 180 |
| *NF-kB*, -94 ins/del ATTG | 92 | 10 | 174 | 2 | 182 | 2 | 182 |

OV: *Opisthorchis viverrini.*

**Table 2 Relationship between serum anti-*Opisthorchis viverrini* and cholangiocarcinoma risk, Ubon Ratchathani, Thailand**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Number of case-control pairs according to serum anti-OV status: positive (+) *vs* negative (-)** | **Crude OR** | **95%CI** | ***P* value** | **Adjusted1 OR** | **95%CI** | ***P* value** | **Adjusted2 OR** | **95%CI** | ***P* value** |
| **Case (+) / Control (+)** | **Case (+) / Control (-)** | **Case (-) / Control (+)** | **Case (-) / Control (-)** | **LL** | **UL** | **LL** | **UL** | **LL** | **UL** |
| 67 | 23 | 2 | 3 | 11.50 | 2.71 | 48.78 | < 0.001 | 8.96 | 2.06 | 38.99 | 0.001 | 9.40 | 2.16 | 40.85 | 0.003 |

1Adjusted for alcohol consumption and smoking.

2Adjusted for alcohol consumption and smoking. Missing values for these variables were imputed.

OV: *Opisthorchis viverrini;* CCA: Cholangiocarcinoma; LL: Lower limit; UL: Upper limit.

**Table 3 Relationship between serum anti-*Opisthorchis viverrini*, alcohol consumption, and smoking and** **cholangiocarcinoma risk, Ubon Ratchathani, Thailand, shown by analysis for each of the genetic polymorphisms**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Independent variable** | **Gene adjusted for** | **Adjusted1 OR** | **95%CI** | ***P* value** | **Adjusted2 OR** | **95%CI** | ***P* value** |
| **LL** | **UL** | **LL** | **UL** |
| Positive serum anti-OV | *GSTM1* | 9.16  | 2.00  | 41.90  | 0.004  | 7.12  | 1.76  | 28.81  | 0.006  |
|  | *GSTT1* | 8.16  | 1.85  | 35.96  | 0.006  | 7.33  | 1.74  | 30.93  | 0.007 |
|  | *CYP2E1* | 7.75  | 1.73  | 34.69  | 0.007  | 4.90  | 1.41  | 17.05  | 0.013  |
|  | *IL-6*, -174 G/C | 8.07  | 1.80  | 36.07  | 0.006  | 5.39  | 1.51  | 19.29  | 0.010  |
|  | *IL-6*, -634 G/C  | 7.21  | 1.57  | 32.98  | 0.011  | 6.13  | 1.54  | 24.32  | 0.010  |
|  | *IL-10*, -819 T/C | 9.04  | 1.97  | 41.39  | 0.005  | 6.03  | 1.65  | 22.04  | 0.007  |
|  | *NF-kB* | 11.81  | 2.31  | 60.44  | 0.003  | 8.14  | 1.90  | 34.90  | 0.005  |
| Alcohol drinking | *GSTM1* | 1.06  | 0.70  | 1.60  | 0.779  | 1.12  | 0.76  | 1.67  | 0.560  |
|  | *GSTT1* | 1.05  | 0.70  | 1.58  | 0.817  | 1.10  | 0.74  | 1.63  | 0.643 |
|  | *CYP2E1* | 1.05  | 0.70  | 1.58  | 0.801  | 1.10  | 0.75  | 1.63  | 0.614  |
|  | *IL-6*, -174 G/C | 1.03  | 0.68  | 1.56  | 0.907  | 1.09  | 0.73  | 1.62  | 0.674  |
|  | *IL-6*, -634 G/C  | 1.00  | 0.65  | 1.52  | 0.989  | 1.06  | 0.70  | 1.59  | 0.784  |
|  | *IL-10*, -819 T/C | 0.98  | 0.63  | 1.53  | 0.933  | 1.06  | 0.70  | 1.61  | 0.785  |
|  | *NF-kB* | 0.99  | 0.63  | 1.54  | 0.956  | 1.05  | 0.68  | 1.60  | 0.836  |
| Smoking | *GSTM1* | 1.56  | 1.01  | 2.40  | 0.044  | 1.49  | 0.99  | 2.23  | 0.053  |
|  | *GSTT1* | 1.56  | 1.01  | 2.42  | 0.044  | 1.51  | 1.00  | 2.27  | 0.049 |
|  | *CYP2E1* | 1.55 | 1.00  | 2.41 | 0.052 | 1.46 | 0.98  | 2.18 | 0.060 |
|  | *IL-6*, -174 G/C | 1.73 | 1.05  | 2.85 | 0.030 | 1.62 | 1.04  | 2.54 | 0.035 |
|  | *IL-6*, -634 G/C | 1.79 | 1.10  | 2.91 | 0.018 | 1.73 | 1.08  | 2.76 | 0.022 |
|  | *IL-10*, -819 T/C | 1.80 | 1.09  | 2.98 | 0.022 | 1.65 | 1.05  | 2.59 | 0.030 |
|  | *NF-kB* | 1.78 | 1.08  | 2.94 | 0.023 | 1.80 | 1.11  | 2.91 | 0.016 |

1Adjusted for alcohol consumption and smoking.

2Adjusted for alcohol consumption and smoking. Missing values for these variables were imputed.

OV: *Opisthorchis viverrini;* CCA: Cholangiocarcinoma; LL: Lower limit; UL: Upper limit.

**Table 4 Relationship between polymorphisms of drug-metabolizing and inflammation-related enzyme genes and cholangiocarcinoma risk, Ubon Ratchathani, Thailand**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Number of pairs according to gene polymorphism of case and control** | **Polymorphism** | **Crude OR** | **95%CI** | ***P* value** | **Adjusted1 OR** | **95%CI** | ***P* value** | **Adjusted2 OR** | **95%CI** | ***P* value** |
| **LL** | **UL** | **LL** | **UL** | **LL** | **UL** |
| *GSTM1* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Wild | Null |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | Wild | 8 | 18 |  | Wild | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | Null | 18 | 51 |  | Null | 1.00  | 0.52  | 1.92  | 1.000  | 0.67  | 0.29  | 1.56  | 0.357  | 0.81  | 0.37  | 1.75  | 0.594  |
| *GSTT1* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Wild | Null |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | Wild | 44 | 23 |  | Wild | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | Null | 21 | 7 |  | Null | 1.10  | 0.61  | 1.98  | 0.763  | 0.94  | 0.44  | 1.98  | 0.865  | 1.02  | 0.52  | 2.02  | 0.957  |
| *CYP2E1* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | c1/c1 | c1/c2 | c2/c2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | c1/c1 | 56 | 14 | 4 | c1/c1 | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | c1/c2 | 12 | 4 | 2 | c1/c2 | 1.11  | 0.52  | 2.38  | 0.782  | 1.02  | 0.39  | 2.70  | 0.966  | 1.14  | 0.47  | 2.77  | 0.773  |
|  | c2/c2 | 1 | 0 | 0 | c2/c2 | 6.19  | 0.74  | 52.08  | 0.093  | 2.02  | 0.20  | 20.67  | 0.552  | 4.17  | 0.45  | 38.24  | 0.207  |
|  |  |  |  |  |  | c1/c2 or c2/c2 | 1.38  | 0.68  | 2.83  | 0.371  | 1.14  | 0.47  | 2.77  | 0.767  | 1.35  | 0.58  | 3.11  | 0.484  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *IL-6* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case | -174  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | G/G | G/C | C/C |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | G/G | 90 | 0 | 0 | G/G | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | G/C | 1 | 0 | 0 | G/C | 0.00  | - | - | - | 0.003  | 0.00  | - | 0.995  | 0.0037  | 0.00  | - | 0.999  |
|  | C/C | 0 | 0 | 0 | C/C | - | - | - | - | - | - | - | - | - | - | - | - |
| *IL-6* |  |  |  |  |  | -634  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | G/G | G/C | C/C |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | G/G | 0 | 4 | 5 | G/G | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | G/C | 2 | 13 | 12 | G/C | 1.93  | 0.63  | 5.93  | 0.252  | 1.90  | 0.49  | 7.30  | 0.351  | 1.69  | 0.46  | 6.25  | 0.432  |
|  | C/C | 4 | 18 | 34 | C/C | 1.28  | 0.44  | 3.73  | 0.654  | 1.38  | 0.40  | 4.71  | 0.607  | 1.45  | 0.43  | 4.87  | 0.551  |
|  |  |  |  |  |  | G/C or C/C | 1.50  | 0.53  | 4.21  | 0.442  | 1.53  | 0.46  | 5.05  | 0.488  | 1.52  | 0.46  | 4.98  | 0.489  |
| *IL-10* |  |  |  |  |  | -819 T/C |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | T/T | T/C | C/C |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | T/T | 23 | 15 | 6 | T/T | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | T/C | 15 | 17 | 4 | T/C | 0.81  | 0.41  | 1.60  | 0.537  | 0.66  | 0.27  | 1.63  | 0.371  | 0.75  | 0.34  | 1.70  | 0.497  |
|  | C/C | 8 | 0 | 3 | C/C | 1.19  | 0.46  | 3.06  | 0.715  | 1.59  | 0.43  | 5.93  | 0.487  | 1.63  | 0.51  | 5.17  | 0.405  |
|  |  |  |  |  |  | T/C or C/C | 0.91  | 0.51  | 1.65  | 0.763  | 0.85  | 0.39  | 1.87  | 0.686  | 0.95  | 0.47  | 1.93  | 0.891  |
| *NF-kB* |  |  |  |  |  | -94 ins/del ATTG |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Case |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | del/del | ins/del | ins/ins |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Control | del/del | 3 | 5 | 3 | del/del | 1.00  | Reference | 1.00  | Reference | 1.00  | Reference |
|  | ins/del | 4 | 16 | 13 | ins/del | 0.83  | 0.32  | 2.17  | 0.711  | 1.11  | 0.27  | 4.61  | 0.884  | 0.79  | 0.24  | 2.67  | 0.708  |
|  | ins/ins | 9 | 20 | 19 | ins/ins | 0.48  | 0.19  | 1.23  | 0.128  | 0.32  | 0.08  | 1.20  | 0.090  | 0.33  | 0.10  | 1.03  | 0.057  |
|  |  |  |  |  |  | ins/del or ins/ins | 0.91  | 0.51  | 1.65  | 0.763  | 0.49  | 0.14  | 1.69  | 0.258  | 0.47  | 0.16  | 1.38  | 0.167  |

1Adjusted for alcohol consumption and smoking.

2Adjusted for alcohol consumption and smoking. Missing values for these variables were imputed.

CCA: Cholangiocarcinoma; LL: Lower limit; UL: Upper limit.

**Table 5 Risk of cholangiocarcinoma due to the combination of polymorphisms of *GSTT1* and *CYP2E1*: Matched case-control study, Ubon Ratchathani, Thailand**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| ***CYP2E1*** | ***GSTT1* wild** | ***GSTT1* null** | ***CYP2E1*** | ***GSTT1* wild** | ***GSTT1* null** |  |
| **Number** | **Number** | **Odds ratio1** | **95%CI** | ***P* value** | **Odds ratio1** | **95%CI** | ***P* value** | ***P* for interaction** |
| **Case** | **Control** | **Case** | **Control** | **LL** | **UL** | **LL** | **UL** |
| c1/c1 | 49 | 59 | 25 | 18 | c1/c1 | 1.00 | Reference |  | 2.04 | 0.95 | 4.39 | 0.07 | < 0.01 |
| c1/c2 + c2/c2 | 24 | 9 | 5 | 11 | c1/c2 + c2/c2 | 3.33 | 1.23 | 9.00 | 0.02 | 0.54 | 0.14 | 2.13 | 0.38 |

1Based on the conditional logistic regression model.

CCA: Cholangiocarcinoma; CI: Confidence interval; LL: Lower limit; UL: Upper limit.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**